X

Vous n'êtes pas connecté

Rubriques :

  - WN.COM - Health - 22/Jul 10:35

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil® (modafinil), and bring BRIUMVI® (ublituximab) to patients in Australia Sydney, Australia and Düsseldorf, Germany – 22 July 2025 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launch of a new affiliate, Neuraxpharm Australia, led by newly appointed Head of Commercial, Avendran Naidu, as the Company continues to expand globally. The launch of Neuraxpharm Australia...

Articles similaires

Sorry! Image not available at this time

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

wn.com - 22/Jul 10:35

Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS...

Sorry! Image not available at this time

Tom Donnelly appointed as Head of Commercial NAI Harcourts Australia

eliteagent.com - 23/Jul 03:01

Harcourts Australia is proud to announce the appointment of Tom Donnelly as their new Head of Commercial NAI Harcourts Australia. The post Tom...

Sorry! Image not available at this time

Tom Donnelly appointed as Head of Commercial NAI Harcourts Australia

eliteagent.com - 23/Jul 03:01

Harcourts Australia is proud to announce the appointment of Tom Donnelly as their new Head of Commercial NAI Harcourts Australia. The post Tom...

Sorry! Image not available at this time

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

drugs.com - 17/Jul 21:07

BOSTON, July 17, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating...

Sorry! Image not available at this time

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

drugs.com - 17/Jul 21:07

BOSTON, July 17, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating...

Sorry! Image not available at this time

John Talbot to lead Elders’ commercial real estate expansion

eliteagent.com - 18/Jul 02:11

Elders has appointed John Talbot as Head of Commercial Real Estate as the company looks to expand its footprint in the commercial property sector. The...

Sorry! Image not available at this time

Ipsen announces changes to its Executive Committee

financialpost.com - 23/Jul 05:33

PARIS, FRANCE, 23 July 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the...

Sorry! Image not available at this time

Ipsen announces changes to its Executive Committee

financialpost.com - 23/Jul 05:33

PARIS, FRANCE, 23 July 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the...

Sorry! Image not available at this time

Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze

wn.com - 29/Jul 07:40

NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological...

Sorry! Image not available at this time

Gekko Group Appoints Tom Bell Head of Leisure Travel Division

ittn.ie - 18/Jul 14:32

Leading German travel technology company Gekko Group has appointed Tom Bell as chief commercial officer of its leisure travel division. Headquartered...

Les derniers communiqués